(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer

• Status: Completed
• Trial end date: 2008-08-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this trial is to study the effect of adjuvant or immediate hormonal therapy, versus placebo, in subjects who have either undergone a primary therapy (principally radical prostatectomy or radiotherapy) or who were otherwise to be managed by watchful waiting.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Bicalutamide

Criteria

Inclusion Criteria:

• Clinical diagnosis of non-metastatic cancer of the prostate gland

• Patient to be 18 years and above

Exclusion Criteria:

• Previous systemic therapy for prostate cancer

• Previous history of another form of cancer (not prostate) within 5 years of study start.